Harvoni
Drug
Gilead Sciences Inc
Total Payments
$29.3M
Transactions
4,522
Doctors
671
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $146,247 | 10 | 0 |
| 2022 | $1.4M | 69 | 0 |
| 2021 | $2.5M | 352 | 4 |
| 2020 | $4.2M | 512 | 29 |
| 2019 | $5.4M | 732 | 86 |
| 2018 | $6.1M | 1,117 | 128 |
| 2017 | $9.5M | 1,730 | 532 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $29.1M | 3,513 | 99.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $86,760 | 36 | 0.3% |
| Food and Beverage | $38,097 | 915 | 0.1% |
| Travel and Lodging | $10,261 | 47 | 0.0% |
| Consulting Fee | $7,320 | 11 | 0.0% |
Payments by Type
Research
$29.1M
3,513 transactions
General
$142,438
1,009 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials | Gilead Sciences, Inc. | $13.9M | 0 |
| A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials | Gilead Sciences Inc | $5.3M | 0 |
| Chronic Hepatitis B and C Cohort Study (CHeCS) | Gilead Sciences, Inc. | $1.4M | 0 |
| Chronic Hepatitis B and C Cohort Study (CHeCS) | Gilead Sciences Inc | $772,037 | 0 |
| Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda (PCT) in Subjects with Chronic Hepatitis C (CHC) | Gilead Sciences Inc | $494,326 | 0 |
| Phase II Open-Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects with Hepatitis B Virus Infection (APOSTLE) | Gilead Sciences, Inc. | $420,383 | 0 |
| A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children with Chronic HCV-Infection | Gilead Sciences, Inc. | $401,101 | 0 |
| A MULTICENTER, OPEN-LABEL STUDY OF SOFOSBUVIR TREATMENT REGIMENS IN SUBJECTS INFECTED WITH CHRONIC HEPATITIS C AND ADVANCED HEART FAILURE OR LUNG DISEASE | Gilead Sciences, Inc. | $399,300 | 0 |
| Curing HCV in Incarcerated Patients (CHIP) | Gilead Sciences, Inc. | $388,839 | 0 |
| Patient-Centered Models of HCV Care for People who Inject Drugs | Gilead Sciences, Inc. | $381,672 | 0 |
| GRAVITY: Geomapping Resistance and Viral Transmission in Risky Populations | Gilead Sciences, Inc. | $357,130 | 0 |
| Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda (PCT) in Subjects with Chronic Hepatitis C (CHC) | Gilead Sciences, Inc. | $348,942 | 0 |
| A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children with Chronic HCV-Infection | Gilead Sciences Inc | $347,310 | 0 |
| Early and late treatment of Hepatitis C with Sofosbuvir/Ledipasvir in Liver Transplant Recipients | Gilead Sciences, Inc. | $341,263 | 0 |
| Early and late treatment of Hepatitis C with Sofosbuvir/Ledipasvir in Liver Transplant Recipients | Gilead Sciences Inc | $338,258 | 0 |
| A Phase IV Pilot Study to Assess Community-based Treatment Efficacy in Chronic Hepatitis C Monoinfection and Coinfection with HIV in the District of Columbia (ASCEND) | Gilead Sciences Inc | $301,490 | 0 |
| Building Novel Models of Healthcare Delivery for Patients with Hepatitis C Virus | Gilead Sciences, Inc. | $282,937 | 0 |
| RESCUE: A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Subjects Who Have Failed Prior Treatment With Sofosbuvir-based Therapies | Gilead Sciences Inc | $255,604 | 0 |
| Implementation and Evaluation of Care Coordination in Linkage to Care for Hepatitis C Following Release from New York City Jails | Gilead Sciences Inc | $253,595 | 0 |
| A Phase IV Pilot Study to Assess Community-based Treatment Efficacy in Chronic Hepatitis C Monoinfection and Coinfection with HIV in the District of Columbia (ASCEND) | Gilead Sciences, Inc. | $193,815 | 0 |
Top Doctors Receiving Payments for Harvoni
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $29.1M | 3,513 |
| , MD | Internal Medicine | Atlanta, GA | $9,302 | 16 |
| , M.D | Gastroenterology | San Antonio, TX | $6,621 | 6 |
| , M.D | Gastroenterology | Norfolk, VA | $5,588 | 6 |
| , MD | Transplant Hepatology | Philadelphia, PA | $5,000 | 2 |
| Ricardo Franco | Infectious Disease | Birmingham, AL | $4,739 | 11 |
| , MD | Transplant Surgery | Los Angeles, CA | $4,573 | 9 |
| , MD | Gastroenterology | Seattle, WA | $4,503 | 6 |
| , M.D | Addiction Medicine | Rancho Cordova, CA | $4,080 | 2 |
| , DO | Gastroenterology | Allentown, PA | $4,027 | 6 |
| , MD | Internal Medicine | Coronado, CA | $3,666 | 8 |
| , M.D | Gastroenterology | Fall River, MA | $3,433 | 3 |
| , MD | Gastroenterology | Columbia, MD | $3,279 | 3 |
| , M.D | Specialist | West Hollywood, CA | $3,000 | 1 |
| , M.D | Gastroenterology | Phoenix, AZ | $2,945 | 9 |
| , M.D | Gastroenterology | Indianapolis, IN | $2,567 | 3 |
| , MD FACG AGAF | Gastroenterology | Smithfield, NC | $2,527 | 2 |
| , M.D | Transplant Hepatology | Atlanta, GA | $2,500 | 1 |
| , M.D | Gastroenterology | San Antonio, TX | $2,500 | 1 |
| Josh Levitsky | — | Chicago, IL | $2,500 | 1 |
| , MD | Family Medicine | San Pablo, CA | $2,406 | 8 |
| , M.D | Transplant Hepatology | Washington, DC | $2,184 | 3 |
| , D.O | Internal Medicine | Lansing, MI | $2,052 | 2 |
| , M.D | Gastroenterology | Brooklyn, NY | $2,052 | 2 |
| Vinay Sundaram | — | West Hollywood, CA | $2,040 | 2 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $20.1M
- Gilead Sciences Inc $9.2M
Product Information
- Type Drug
- Total Payments $29.3M
- Total Doctors 671
- Transactions 4,522
About Harvoni
Harvoni is a drug associated with $29.3M in payments to 671 healthcare providers, recorded across 4,522 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2023. In 2023, $146,247 was paid across 10 transactions to 0 doctors.
The most common payment nature for Harvoni is "Unspecified" ($29.1M, 99.5% of total).
Harvoni is associated with 20 research studies, including "A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials" ($13.9M).